[Noopept in the treatment of mild cognitive impairment in patients with stroke]

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(10 Pt 1):44-6.
[Article in Russian]


Noopept is a neuroprotector and nootropics. Literature data revealed the treatment effect of noopept on mild cognitive impairment in patients with discirculatory encephalopathy. The present open prospective study included 60 patients with stroke treated with noopept during 12 months. Cognitive functions were assessed before and after treatment using neuropsychological tests. An analysis of MMSE scores and lateral and categorical associations revealed the significant improvement of cognitive functions after 2 months in patients of the main group compared to the controls. The global assessment of efficacy revealed the mild improvement in the main group while no changes were found in the control group. The results have demonstrated that noopept, used in dose 20 mg daily during 2 months, improves cognitive functions in stroke patients and has a high level of safety.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Cognition Disorders / drug therapy*
  • Cognition Disorders / etiology
  • Dipeptides / administration & dosage
  • Dipeptides / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / therapeutic use*
  • Stroke / complications*
  • Treatment Outcome


  • Dipeptides
  • Neuroprotective Agents
  • ethyl phenylacetyl-Pro-Gly